We observed a dramatic attenuation of plasma NfL levels with treatment, speaking to the neuroprotective effects of ATH-1105, even within the context of an aggressive genetically driven model of ALS. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.